De-JAKing resistance with CDK7 inhibitors in post-MPN sAML

Affiliations

Editorial

Lucio H Castilla. Blood. 2025.

. 2025 Feb 6;145(6):556-557.

doi: 10.1182/blood.2024027365.

No abstract available

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML.
Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell CE, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores LB, Loghavi S, DiNardo C, Su X, Rampal RK, Bhalla KN. Fiskus W, et al. Blood. 2025 Feb 6;145(6):612-624. doi: 10.1182/blood.2024026388. Blood. 2025. PMID: 39561280

1. Fiskus W, Mill CP, Bose P, et al. Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025;145(6):612–624. - PubMed
1. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–4053. - PubMed
1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. - PMC - PubMed
1. Song X, Fang C, Dai Y, et al. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer. Br J Cancer. 2024;130(8):1239–1248. - PMC - PubMed
1. Yao Y, Ng JF, Park WD, et al. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023;141(23):2841–2852. - PMC - PubMed